Regeneron's expanded collaboration with CytomX adds two new targets to the $4 billion conditional bispecific antibody partnership, driving demand for specialized biologics manufacturing and Probody masking technology.

Lupin's Ranluspec becomes the first interchangeable ranibizumab biosimilar approved in the US with both vial and pre-filled syringe presentations, opening new opportunities for ophthalmic API suppliers and fill-finish manufacturers.

CordenPharma acquisition of AmbioPharm marks a pivotal moment in the global peptide CDMO landscape. As GLP-1 demand surges, this deal consolidates manufacturing capacity across the U.S. and China.

The FDA has accepted Genentech NDA for giredestrant, the first oral SERD with positive Phase III results in early-stage breast cancer. Priority Review status signals potential approval by November 2026, creating significant new API demand opportunities.